Theseus Pharmaceuticals, Inc.
NASDAQ:THRX
4.06 (USD) • At close February 13, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | Theseus Pharmaceuticals, Inc. |
Symbool | THRX |
Munteenheid | USD |
Prijs | 4.065 |
Beurswaarde | 181,498,998 |
Dividendpercentage | 0% |
52-weken bereik | 2.05 - 12.37 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Dr. Timothy P. Clackson Ph.D. |
Website | https://theseusrx.com |
An error occurred while fetching data.
Over Theseus Pharmaceuticals, Inc.
Theseus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of targeted therapies for the treatment of cancer patients. Its lead product candidate is THE-630, a pan-KIT inhibitor for the treatment of gastrointestinal stromal tumors, which is in Phase I clinical trial. The company also develops fourth-generation
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)